"Duchenne Multiple Dystrophy (DMD) is one of the world’s most...

"Duchenne Multiple Dystrophy (DMD) is one of the world’s most common “rare” and fatal genetic disorders that affects roughly one in every 3,500 to 5000 males. Antisense Therapeutics is a publicly-listed Australian biotech company aimed at developing, testing and commercialising novel treatments for DMD and other rare diseases such as Relapsing-remitting Multiple Sclerosis (RRMS). These treatments are based on a new class of drugs called antisense molecules. ANP has licensed this antisense technology from leading drug discovery and development company Ionis Pharmaceuticals Inc to develop an antisense inhibitor called ATL1102 for the treatment of (DMD). To date, ANP has raised A$7.3 million in oversubscribed Placement, they have applied for dual listing on the Frankfurt Stock Exchange (FSE) and they have received a positive opinion from the European Medicines Agency Committee for Orphan Drug Designation of ATL1102."
http://*.com.au/the-insider/?utm_campaign=Meet%20The%20CEOs&utm_medium=email&_hsmi=99886176&_hsenc=p2ANqtz-8JgWLrKuyRvr4tWbFdep2KNrxT-hWlRqb2yGT6Zfyp6S1Bqrw-3ZY0ake36GjSp-UF3lJYRylaoloF4c-bMKwABNnrgQ&utm_content=99886176&utm_source=hs_email